- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT04011865
Robot-assisted vs Laparoscopic Radical Prostatectomy for Prostate Cancer Treatment
12 juli 2020 bijgewerkt door: Binh Dan Hospital
This study is to compare the outcomes of robotic-assisted laparoscopic radical prostatectomy (RARP) and laparoscopic radical prostatectomy (LRP) for prostate cancer treatment in terms of perioperative surgical, functional and oncological outcomes.
Studie Overzicht
Toestand
Onbekend
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
Participants will either have robotic-assisted laparoscopic radical prostatectomy (RARP) or laparoscopic radical prostatectomy (LRP) as determined by the treating surgeon.
All participants will undergo tests and questionnaires to determine urinary and erectile function, biopsies to determine perioperative surgical, functional and oncological outcomes.
These assessments will be conducted pre-operatively, post-operatively and at certain follow-up time points up to 12 months.
Studietype
Ingrijpend
Inschrijving (Verwacht)
80
Fase
- Niet toepasbaar
Contacten en locaties
In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.
Studie Locaties
-
-
-
Ho Chi Minh City, Vietnam, 700000
- Werving
- Binh Dan Hospital
-
Contact:
- Hoang PC Nguyen, Associate Professor, MD, PhD
- Telefoonnummer: +84 913 719 346
- E-mail: npchoang@gmail.com
-
-
Deelname Criteria
Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
18 jaar en ouder (Volwassen, Oudere volwassene)
Accepteert gezonde vrijwilligers
Nee
Geslachten die in aanmerking komen voor studie
Mannelijk
Beschrijving
Inclusion Criteria:
- Adult men aged 18 years and over;
- Undergoing RARP or LRP. prostatectomy for prostate cancer at Binh Dan Hospital;
- Clinically suitable for radical prostatectomy (cT1-3, No, Mo);
- Cognitively able to give written informed consent for participation;
- Elective procedure.
Exclusion Criteria:
- The patient lacks the ability to consent for themselves;
- Patients unwilling to undergo pre- and post-operative evaluation according to the protocol;
Studie plan
Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Niet-gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Actieve vergelijker: Robotic-assisted surgery
|
The patients diagnosed with prostate cancer (local or locally advanced stages) will be allocated to the study for performing radical prostatectomy surgery.
|
|
Sham-vergelijker: Laparoscopic surgery
|
The patients diagnosed with prostate cancer (local or locally advanced stages) will be allocated to the study for performing radical prostatectomy surgery.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
The console time
Tijdsspanne: During the surgery
|
The time which surgeon spends on the robot console by minuite
|
During the surgery
|
|
Mean of blood loss
Tijdsspanne: During the surgery
|
Milliliter
|
During the surgery
|
|
Perioperative transfusion rate (%)
Tijdsspanne: Up to 1 month after operation
|
The number of cases which will be transfused.
|
Up to 1 month after operation
|
|
The rate of positive surgical margins, extracapsular extension, seminal vesicle invasion, (5)perineural invasion, the number of lymph node yield and node involvement,
Tijdsspanne: Up to 1 week after operation
|
Number of cases, based on the result of pathology.
|
Up to 1 week after operation
|
|
Number of blood units transfused
Tijdsspanne: Up to 1 week after operation
|
Milliliter
|
Up to 1 week after operation
|
|
the rate of conversion to open surgery, the rate of intraoperative incidents (%),
Tijdsspanne: Up to 1 weeks after the surgery.
|
Percentage
|
Up to 1 weeks after the surgery.
|
|
The postoperative recovery parameters using Numeric Pain Rating Scale (NPRS),
Tijdsspanne: Up to 3 month after surgery
|
The NPRS is a segmented numeric version of the visual analog scale (VAS) in which a respondent selects a whole number (0-10 integers) that best reflects the intensity of pain, in a total of 10 points, higher score means worse, with 0 means no pain and 10 is the worst pain.
The mean score will be calculated to reflect the post-operative pain.
|
Up to 3 month after surgery
|
|
Change of hemoglobin from baseline
Tijdsspanne: Up to 1 week after operation
|
(mg/mL)
|
Up to 1 week after operation
|
|
The drainage time
Tijdsspanne: Up to 3 months after surgery
|
(day),
|
Up to 3 months after surgery
|
|
To assess urethral catheter time, urethral catheter time
Tijdsspanne: Up to 3 months after surgery
|
(day)
|
Up to 3 months after surgery
|
|
To assess bowel movement recovery time,
Tijdsspanne: Up to 1 week after surgery
|
(day)
|
Up to 1 week after surgery
|
|
To assess postoperative hospital stay
Tijdsspanne: Up to 1 month after surgery
|
(day)
|
Up to 1 month after surgery
|
|
The rate of postoperative complications (including infections)
Tijdsspanne: in day 3, day 7, and 1 month after surgery.
|
Percentage
|
in day 3, day 7, and 1 month after surgery.
|
|
PSA level in blood
Tijdsspanne: Before operation
|
(mg/mL)
|
Before operation
|
|
PSA level in blood
Tijdsspanne: 6 weeks post-operation
|
(mg/mL)
|
6 weeks post-operation
|
|
PSA level in blood
Tijdsspanne: 3 months post-operation
|
(mg/mL)
|
3 months post-operation
|
|
PSA level in blood
Tijdsspanne: 6 months post-operation
|
(mg/mL)
|
6 months post-operation
|
|
PSA level in blood
Tijdsspanne: 12 months post-operation
|
(mg/mL)
|
12 months post-operation
|
|
local and regional recurrences on sonography
Tijdsspanne: through study completion, an average of 1 year
|
including ultrasound when PSA rising or any indication of recurrent
|
through study completion, an average of 1 year
|
|
local and regional recurrences, on MRI
Tijdsspanne: through study completion, an average of 1 year
|
including MRI when PSA rising or any indication of recurrent
|
through study completion, an average of 1 year
|
|
local and regional recurrences, on PET Scan
Tijdsspanne: through study completion, an average of 1 year
|
including PET Scan, when PSA rising or any indication of recurrent
|
through study completion, an average of 1 year
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Evaluating the pre and postoperative lower urinary tract symptoms using Full score of International Prostate Symptoms Scores (IPSS)
Tijdsspanne: Preoperative
|
It contains seven questions related to symptoms related to BPH and one question related to the patient's perceived quality of life.
The symptoms must have been experienced in the last month and each answer is scored from 0 to 5 for a maximum score of 35 points.
The sum score will be calculated and the mean score will be evaluated.
|
Preoperative
|
|
Evaluating the pre and postoperative lower urinary tract symptoms using International Prostate Symptoms Scores (IPSS)
Tijdsspanne: 3 months postoperative
|
It contains seven questions related to symptoms related to BPH and one question related to the patient's perceived quality of life.
The symptoms must have been experienced in the last month and each answer is scored from 0 to 5 for a maximum score of 35 points.
The sum score will be calculated and the mean score will be evaluated.
|
3 months postoperative
|
|
Evaluating the pre and postoperative lower urinary tract symptoms using Full score of International Prostate Symptoms Scores (IPSS)
Tijdsspanne: 6 months, postoperative
|
It contains seven questions related to symptoms related to BPH and one question related to the patient's perceived quality of life.
The symptoms must have been experienced in the last month and each answer is scored from 0 to 5 for a maximum score of 35 points.
The sum score will be calculated and the mean score will be evaluated.
|
6 months, postoperative
|
|
Evaluating the pre and postoperative lower urinary tract symptoms using Full score of International Prostate Symptoms Scores (IPSS)
Tijdsspanne: 12 months postoperative.
|
It contains seven questions related to symptoms related to BPH and one question related to the patient's perceived quality of life.
The symptoms must have been experienced in the last month and each answer is scored from 0 to 5 for a maximum score of 35 points.
The sum score will be calculated and the mean score will be evaluated.
|
12 months postoperative.
|
|
Erectile function assessments questionnaires and scoring using Index of Erectile Function Questionnaire, IIEF5, full score
Tijdsspanne: Preoperative
|
The 15-question International Index of Erectile Function (IIEF) Questionnaire is a validated, multi-dimensional, self-administered investigation that has been found useful in the clinical assessment of erectile dysfunction and treatment outcomes in clinical trials.
A score of 0-5 is awarded to each of the 15 questions that examine the 4 main domains of male sexual function: erectile function, orgasmic function, sexual desire and intercourse satisfaction.
The score ranges from 22 - 25 for Normal erectile function (no ED), 17 - 21 for Mild ED, 12 - 16 for Mild to moderate ED, 8 - 11 for Moderate ED, and from 1 - 7 for Severe ED (5 - 7, if a man had no opportunity to engage in sexual activity).
The mean score will be calculated.
|
Preoperative
|
|
Erectile function assessments questionnaires and scoring using Index of Erectile Function Questionnaire, IIEF5, full score
Tijdsspanne: 3 months, postoperative
|
The 15-question International Index of Erectile Function (IIEF) Questionnaire is a validated, multi-dimensional, self-administered investigation that has been found useful in the clinical assessment of erectile dysfunction and treatment outcomes in clinical trials.
A score of 0-5 is awarded to each of the 15 questions that examine the 4 main domains of male sexual function: erectile function, orgasmic function, sexual desire and intercourse satisfaction.
The score ranges from 22 - 25 for Normal erectile function (no ED), 17 - 21 for Mild ED, 12 - 16 for Mild to moderate ED, 8 - 11 for Moderate ED, and from 1 - 7 for Severe ED (5 - 7, if a man had no opportunity to engage in sexual activity).
The mean score will be calculated.
|
3 months, postoperative
|
|
Erectile function assessments questionnaires and scoring using Index of Erectile Function Questionnaire, IIEF5, full score
Tijdsspanne: 6 months, postoperative.
|
The 15-question International Index of Erectile Function (IIEF) Questionnaire is a validated, multi-dimensional, self-administered investigation that has been found useful in the clinical assessment of erectile dysfunction and treatment outcomes in clinical trials.
A score of 0-5 is awarded to each of the 15 questions that examine the 4 main domains of male sexual function: erectile function, orgasmic function, sexual desire and intercourse satisfaction.
The score ranges from 22 - 25 for Normal erectile function (no ED), 17 - 21 for Mild ED, 12 - 16 for Mild to moderate ED, 8 - 11 for Moderate ED, and from 1 - 7 for Severe ED (5 - 7, if a man had no opportunity to engage in sexual activity).
The mean score will be calculated.
|
6 months, postoperative.
|
|
Erectile function assessments questionnaires and scoring using Index of Erectile Function Questionnaire, IIEF5, full score
Tijdsspanne: 12 months postoperative
|
The 15-question International Index of Erectile Function (IIEF) Questionnaire is a validated, multi-dimensional, self-administered investigation that has been found useful in the clinical assessment of erectile dysfunction and treatment outcomes in clinical trials.
A score of 0-5 is awarded to each of the 15 questions that examine the 4 main domains of male sexual function: erectile function, orgasmic function, sexual desire and intercourse satisfaction.
The score ranges from 22 - 25 for Normal erectile function (no ED), 17 - 21 for Mild ED, 12 - 16 for Mild to moderate ED, 8 - 11 for Moderate ED, and from 1 - 7 for Severe ED (5 - 7, if a man had no opportunity to engage in sexual activity).
The mean score will be calculated.
|
12 months postoperative
|
|
The quality of life questionnaires and scoring using the the Short Form (36) Health Survey questionnaire
Tijdsspanne: Preoperative
|
The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section.
Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight.
The lower the score the more disability.
The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.
The mean score will be calculated.
|
Preoperative
|
|
The quality of life questionnaires and scoring using the the Short Form (36) Health Survey questionnaire
Tijdsspanne: 3 months, postoperative.
|
The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section.
Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight.
The lower the score the more disability.
The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.
The mean score will be calculated.
|
3 months, postoperative.
|
|
The quality of life questionnaires and scoring using the the Short Form (36) Health Survey questionnaire
Tijdsspanne: 6 months, postoperative
|
The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section.
Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight.
The lower the score the more disability.
The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.
The mean score will be calculated.
|
6 months, postoperative
|
|
The quality of life questionnaires and scoring using the the Short Form (36) Health Survey questionnaire
Tijdsspanne: 12 months postoperative
|
The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section.
Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight.
The lower the score the more disability.
The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.
The mean score will be calculated.
|
12 months postoperative
|
Medewerkers en onderzoekers
Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.
Sponsor
Onderzoekers
- Studie directeur: Hung V Tran, MD, PhD, Binh Dan Hospital
Studie record data
Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.
Bestudeer belangrijke data
Studie start (Werkelijk)
1 januari 2019
Primaire voltooiing (Verwacht)
31 december 2020
Studie voltooiing (Verwacht)
31 december 2020
Studieregistratiedata
Eerst ingediend
13 mei 2019
Eerst ingediend dat voldeed aan de QC-criteria
4 juli 2019
Eerst geplaatst (Werkelijk)
9 juli 2019
Updates van studierecords
Laatste update geplaatst (Werkelijk)
14 juli 2020
Laatste update ingediend die voldeed aan QC-criteria
12 juli 2020
Laatst geverifieerd
1 juli 2020
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- BD022019
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
NEE
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Nee
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Nee
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .